CERo Therapeutics Holdings, Inc. - Common Stock CERO 深 沪
等待开盘 08-14 09:30:00 美东时间
8.25
+0.280
+3.51%
华盛通- 最 高8.25
- 今 开8.00
- 成交量 3.25万股
- 最 低 7.935
- 昨 收 7.97
- 总市值 318.53万
- 52周最高 895.40
- 市盈率 静 --
- 换手率 8.42%
- 52周最低 6.80
- 委 比 -84.29%
- 总股本 38.61万
- 历史最高 24760.00
- 量 比 2.00
- 振 幅 3.95%
- 历史最低 7.935
- 每 手 1
- 风险率 124.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CERo Therapeutics Doses Second Patient In Phase 1 AML Trial; Reports Early Pharmacokinetic Data With More Than Seven Days Passed Following The Second Patient's Infusion, Monitoring Continues For Key Safety, Tolerability, And Efficacy Endpoints
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic resultsSOUTH SAN FRANSCISCO, Calif., July 31, 2025 (GLOBE
07-31 20:11
CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236
South San Francisco-based CERo Therapeutics Holdings, Inc. has dosed the second patient in the Phase 1 CER-1236 clinical trial targeting acute myeloid leukemia (AML). The trial aims to evaluate the safety and efficacy of the novel CAR-T therapeutic candidate, CER-1236, which uses phagocytic mechanisms to destroy cancer cells. The first patient showed promising pharmacokinetic results with significant cell expansion post-infusion. The study is cur...
07-31 12:10
美股大行评级 | 买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元
买入！Darden Restaurants获多家大行上调目标价；瑞银维持特斯拉"卖出"评级，目标价升至215美元>>
06-24 10:07
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
CERo Therapeutics has announced the successful completion of the initial evaluation for its lead compound, CER-1236, in a Phase 1 clinical trial targeting acute myeloid leukemia (AML). The first patient showed no dose-limiting toxicities, with the second patient scheduled for dosing shortly. Robert Sikorski, CERo’s CMO, emphasized the promising results following the successful manufacturing of CER-1236. CEO Chris Ehrlich expressed confidence in t...
06-23 12:15
What's Going On With Cero Therapeutics Stock Tuesday?
CERo Therapeutics Holdings Inc (NASDAQ:CERO) shares are trading higher Tuesday after the company received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for CER-1236.
06-17 22:03
CERo Therapeutics Gains FDA Orphan Drug Designation
CERo Therapeutics Holdings ( ($CERO) ) has shared an update. On June 17, 2025, ...
06-17 20:47
Market-Moving News for June 17th
APPS: 16% | Digital Turbine shares are trading higher after reporting better-than-expected Q4 EPS and sales. RDW: -13% | Redwire shares are trading lower after the company announced a $200 million common
06-17 19:12
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
US FDA grants orphan drug designation to CERo's CER-1236 for acute myeloid leukemia. CER-1236 is an engineered T cell therapy leveraging phagocytic mechanisms and is currently in Phase 1 clinical trials. The designation qualifies CERo for incentives like clinical trial assistance and market exclusivity, highlighting potential for innovative AML treatment.
06-17 12:15
